A study of 44 cases of pure dysgerminoma of the ovary: a single institutional experience
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250184Keywords:
Pure dysgerminoma, Malignant germ cell tumors, Neoadjuvant chemotherapy, Fertility-sparing surgeryAbstract
Background: The extent of surgery and additional therapy required in patients with dysgerminoma is debated. This study evaluated the clinicopathologic characteristics, treatment modalities, long-term survival, and menstrual and fertility outcomes of women with ovarian dysgerminoma managed at our institute.
Methods: A total 44 histologically proven pure ovarian dysgerminoma cases were identified in this retrospective study. Patients who received treatment between 2006 and 2017 at Gujarat Cancer and Research Institute, either surgery or chemotherapy, or both were included.
Results: About 60.6% of patients presented with stage I, 9.09% with stage II, 27.27% with stage III, and 3.03% with stage IV disease. Initial management was surgery followed by observation in 9 (20.45%), surgery followed by adjuvant chemotherapy in 25 (56.81%), and neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy in 9 (20.45%) patients. Recurrence occurred in 1 (2.32%) patient with stage III disease after 1 year and 5 months (17 months) post-chemotherapy successfully salvaged with platinum-containing chemotherapy. The 3-year disease-free survival (DFS) and overall survival (OS) were 93.18% and 95.45%, respectively. Thirteen patients attempted conception and 6 (46.15%) delivered after treatment completion. Thirty-five patients underwent fertility-sparing surgery. Out of these, thirty patients (85.7%) got regular menstrual cycles. All three prepubertal girls attained menarche.
Conclusions: Regardless of the stage, fertility-sparing surgery can be offered to the patient with good reproductive outcomes expected after fertility-sparing surgery followed by chemotherapy. Adjuvant chemotherapy is associated with significant improvement in DFS. NACT followed by surgery is a reasonable option for patients with advanced-stage dysgerminoma.
Metrics
References
Friedman M, White RG, Nissenbaum MM, Browde S. Serum lactic dehydrogenase-A possible tumor marker for an ovarian dysgerminoma: A literature review and a report of a case. Obstet Gynecol Surv. 1984;39:247-51. DOI: https://doi.org/10.1097/00006254-198405000-00001
Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, editors. DiSaia and Creasman Clinical Gynecologic Oncology. 10th edition. Elsevier. 2023;282-310.e7. DOI: https://doi.org/10.1016/B978-0-323-77684-4.00019-2
Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, et al; Children's Oncology Group (COG). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004;39(3):424-9. DOI: https://doi.org/10.1016/j.jpedsurg.2003.11.027
Michener CM. Ovarian Dysgerminomas Treatment & Management. In: Randall LM, editor. Drugs & Diseases Obstetrics & Gynecology. 2024. Medscape. Available at: https://emedicine.medscape.com/article/ 253701-treatment. Accessed on 25 October 2024.
Tîrnovanu MC, Florea ID, Tănase A, Toma BF, Cojocaru E, Ungureanu C, et al. Uncommon Metastasis of Ovarian Dysgerminoma: A Case Report and Review of the Literature. Medicina (Kaunas). 2021;57(6):534. DOI: https://doi.org/10.3390/medicina57060534
Berek JS, Bast RC Jr. Nonepithelial Ovarian Cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker. 2003.
Vicus D, Beiner ME, Klachook S, Le LW, Laframboise S, Mackay H. Pure dysgerminoma of the ovary 35 years on: a single institutional experience. Gynecol Oncol. 2010;117(1):23-6. DOI: https://doi.org/10.1016/j.ygyno.2009.12.024
Patterson DM, Murugaesu N, Holden L, Seckl MJ, Rustin GJ. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43-50. DOI: https://doi.org/10.1111/j.1525-1438.2007.00969.x
Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Eur J Cancer. 2021;148:124-33. DOI: https://doi.org/10.1016/j.ejca.2021.02.022
Canlorbe G, Chabbert-Buffet N, Uzan C. Fertility-Sparing Surgery for Ovarian Cancer. J Clin Med. 2021;10(18):4235. DOI: https://doi.org/10.3390/jcm10184235
Hyseni N, Llullaku S, Jashari H, Zahiti K, Hyseni F, Kurshumliu F, et al. Advanced ovarian dysgerminoma infiltrating both ovaries and uterus in a 7-year-old girl. Case Rep Oncol Med. 2014;2014:910852. DOI: https://doi.org/10.1155/2014/910852
Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med. 2005;50(6):417-25.
Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, et al; Pediatric Oncology Group 9048; Children's Cancer Group 8891. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol. 2004;22(17):3563-9. DOI: https://doi.org/10.1200/JCO.2004.01.006
Talukdar S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol. 2014;132(1):28-32. DOI: https://doi.org/10.1016/j.ygyno.2013.10.009
Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 1998;16(10):3386-91. DOI: https://doi.org/10.1200/JCO.1998.16.10.3386
Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89(2):391-8. DOI: https://doi.org/10.1002/1097-0142(20000715)89:2<391::AID-CNCR26>3.0.CO;2-V
Yoo SC, Kim WY, Yoon JH, Chang SJ, Chang KH, Ryu HS. Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy. Acta Obstet Gynecol Scand. 2010;89(1):126-30. DOI: https://doi.org/10.3109/00016340903348383
Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999;17(9):2670. DOI: https://doi.org/10.1200/JCO.1999.17.9.2670
Anita AN, Rushdan MN. Reproductive function after treatment of ovarian germ cell malignancy. Med J Malaysia. 2012;67:71-6.
Al Husaini H, Soudy H, El Din Darwish A, Ahmed M, Eltigani A, Al Mubarak M, et al. Pure dysgerminoma of the ovary: a single institutional experience of 65 patients. Med Oncol. 2012;29(4):2944-8. DOI: https://doi.org/10.1007/s12032-012-0194-z
Kdous M, Hachicha R, Gamoudi A, Boussen H, Benna F, Rahal K. Pure dysgerminoma of the ovary. 12 case reports. Tunis Med. 2003;81(12):937-43.
Downloads
Published
How to Cite
Issue
Section
